1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Corticosteroid Implants (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

Corticosteroid Implants (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023


Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Corticosteroids have demonstrated a range of pharmacological actions, including inhibition of inflammation, inhibition of the release of certain inflammatory cytokines, and suppression of VEGF secretion, highlighting this type of biological agent as a potential treatment for various ocular conditions, including DME, dAMD, wAMD, and RVO.Corticosteroids have been used off-label for many years as a treatment for ME and wAMD due to their ability to inhibit inflammation and the release of certain inflammatory cytokines, supress VEGF secretion, and reduce the vascular permeability of the retina.


- Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Corticosteroid Implants including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Corticosteroid Implants for the top six countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain and the UK

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Corticosteroid Implants performance.
- Obtain sales forecast for Corticosteroid Implants from 2013-2023 in top six countries (the US, France, Germany, Italy, Spain and the UK).

Table Of Contents

Corticosteroid Implants (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
1 Table of Contents
2 Introduction 11
2.1 Related Reports 12
3 Disease Overview 14
3.1 Macular Degeneration Overview 14
3.1.1 Etiology and Pathophysiology 16
3.1.2 Classification 20
3.1.3 Symptoms and Diagnosis 22
3.2 Macular Edema Overview 25
3.2.1 Etiology and Pathophysiology 26
3.2.2 Classification 29
3.2.3 Symptoms and Diagnosis 30
4 Disease Management 33
4.1 Diagnosis and Treatment Overview 33
4.1.1 Macular Edema Diagnosis 33
4.1.2 Macular Degeneration Diagnosis 33
4.1.3 Treatment Guidelines and Leading Prescribed Drugs 34
4.1.4 Clinical Practice 36
5 Competitive Assessment 50
5.1 Overview 50
6 Corticosteroid Implants 52
6.1 Overview 52
6.1.1 Ozurdex 52
6.1.2 Retisert 55
6.1.3 Iluvien 55
6.2 Efficacy - Diabetic Macular Edema 59
6.3 Safety 60
6.4 SWOT Analysis 62
6.5 Forecast 62
7 Appendix 64
7.1 Bibliography 64
7.2 Abbreviations 77
7.3 Methodology 81
7.4 Forecasting Methodology 81
7.4.1 Diagnosed ME and AMD Patients 81
7.4.2 Percentage of Drug-Treated Patients 82
7.4.3 General Pricing Assumptions 82
7.4.4 Individual Drug Assumptions 83
7.5 Primary Research - KOLs Interviewed for this Report 84
7.6 Primary Research - High-Prescribers Survey 85
7.7 About the Authors 86
7.7.1 Analyst 86
7.7.2 Therapy Area Director 86
7.7.3 Global Head of Healthcare 87
7.8 About GlobalData 88
7.9 Disclaimer 88

1.1 List of Tables

Table 1: ARM System Classification of AMD 21
Table 2: Symptoms of AMD 22
Table 3: National and International Treatment Guidelines for ME and AMD 35
Table 4: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013 36
Table 5: Leading Treatments for ME and AMD, 2014 51
Table 6: Product Profile - Ozurdex 54
Table 7: Product Profile - Iluvien 58
Table 8: Corticosteroid IVT Implants SWOT Analysis, 2014 62
Table 9: Global Sales Forecast ($m) for Ozurdex, 2013-2023 63
Table 10: Global Sales Forecast ($m) for Iluvien, 2013-2023 63
Table 11: Surveyed High-Prescribing Physicians (Non-KOLs), by Country 85

1.2 List of Figures

Figure 1: Anatomy of the Eye and Macula 14
Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD 23
Figure 3: Color Fundus Photographs of Dry and Wet AMD 23
Figure 4: FAF Imaging of GA 24
Figure 5: Imaging of wAMD 25
Figure 6: CMT in DME 31
Figure 7: RVOs (BRVO and CRVO) on an FA 32
Figure 8: Increased CRT in ME-RVO 32
Figure 9: ME Clinical Treatment Flowchart 42
Figure 10: AMD Clinical Treatment Flowchart 49
Figure 11: Iluvien's and Ozurdex's Clinical Development in wAMD, dAMD, and DME 59

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8 085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8 085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Opioid Market in the US

  • October 2016
    32 pages
  • Opioid  


    Infectious Dise...  

  • United States  



View report >

Related Market Segments :

Eye Disease


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.